Article
Efavirenz as a potential drug for the treatment of triple-negative breast cancers.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Feb 2021
Chiou P-T, Ohms S, Board P G, Dahlstrom J E, Rangasamy D, Casarotto M G
Abstract excerpt
PURPOSE: In contrast to hormone receptor driven breast cancer, patients presenting with triple-negative breast cancer (TNBC) often have limited drug treatment options. Efavirenz, a non-nucleoside reverse transcriptase (RT) inhibitor targets abnormally overexpressed long interspersed nuclear element 1 (LINE-1) RT and has been shown to be a promising anticancer agent for treating prostate and pancreatic cancers....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.